Hepatocellular carcinoma (HCC) is challenging to diagnose and has an evolving treatment landscape, which makes a multidisciplinary approach to care important to ensure high-quality care and the best patient outcomes.
Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related deaths in the United States, but HCC is challenging to diagnose because clinical presentation varies, and symptoms often appear late in the disease course.
The unique challenges of HCC diagnosis necessitates a multidisciplinary approach to ensure high-quality care and the best patient outcomes, according to a study published in Clinical Liver Disease. Because the majority of HCC cases have a background of cirrhosis, gastroenterologists are pivotal for screening, for instance.
The treatment landscape continues to evolve, and finding the right treatment requires “expertise in the various therapeutic modalities from a number of different specialties, including hepatology, hepatobiliary surgery, transplant surgery, radiation oncology, medical oncology, interventional radiology, and palliative care specialists, among others,” the authors explained.
Although HCC can be cured with liver transplantation, surgical resection, or thermal ablation, nearly 70% of patients are not candidates and need alternative treatment options. A common practice for multidisciplinary care in cancer is to conduct regular meetings, known as multidisciplinary tumor boards (MTBs), to present cases and review relevant treatments. The authors noted that patients discussed at MTBs had improved treatment and better outcomes, including overall survival and a greater likelihood of undergoing liver transplantation.
“Moreover, recent studies have also shown that MTB frequently leads to changes in imaging interpretation, thus impacting potential treatment recommendations,” they added.
Another model of multidisciplinary care is a centralized group clinic model where patients see the appropriate providers concurrently. These appointments can either occur in person (space permitting) or virtually. This approach is patient centered and allows patients to actively participate in the discussion of their care. These clinics have resulted in shorter time to treatment and improved survival.
In addition to treatment benefits, such multidisciplinary approaches have resulted in improved patient satisfaction, specifically related to communication and confidence in their physician, the authors wrote.
There are multiple challenges to effectively implementing successful multidisciplinary care, but they can be successful even in resource-scarce regions, they noted, with one study showing successful implementation in a small community environment. Success of multidisciplinary care is reliant on administrative support, effective leadership, and team dynamics, they added.
“In today’s evolving landscape with newly available cancer treatments readily available, the importance of an integrated multidisciplinary approach to HCC care is vital,” the authors concluded.
Reference
Salgia R, Mendiretta V. The multidisciplinary management of hepatocellular carcinoma. Clin Liver Dis (Hoboken). 2021;17(6):405-408. doi:10.1002/cld.1068
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More